Sugi Predict

Sugi Predict / Compounds / SCHEMBL22835653

SCHEMBL22835653

SCHEMBL22835653

Cn1c(=O)n(C2CCC(=O)NC2=O)c2cccc(CN3CCOC4(CCN(C(=O)OC(C)(C)C)CC4)C3)c21

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 11/20 0.41
▸ CRBN Q96SW2 11/20 0.41
▸ MGLL Q99685 7/20 0.41
▸ CCR5 P51681 1/20 0.37
▸ BRD9 Q9H8M2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21997271 0.92 DDB1 (0.40) DDB1CRBNMGLLCCR5BRD9
SCHEMBL21998255 0.88 DDB1 (0.45) DDB1CRBNCCR5
SCHEMBL21996732 0.88 DDB1 (0.46) DDB1CRBNCCR5
SCHEMBL21997665 0.87 DDB1 (0.48) DDB1CRBNCCR5
SCHEMBL21997900 0.87 DDB1 (0.39) DDB1CRBNMGLLCCR5BRD9
SCHEMBL21996994 0.85 DDB1 (0.45) DDB1CRBNCCR5
SCHEMBL22835859 0.85 CRBN (0.48) DDB1CRBN
SCHEMBL26635060 0.85 DDB1 (0.46) DDB1CRBNCCR5
SCHEMBL22836532 0.84 DDB1 (0.47) DDB1CRBNCCR5
SCHEMBL21997604 0.84 DDB1 (0.45) DDB1CRBNCCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 — — EP disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 DDB1 511/4885CRBN 39/4885MGLL 4268/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 DDB1 2480/4885CRBN 79/4885MGLL 4320/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885MGLL 1244/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 DDB1 68/4885CRBN 322/4885MGLL 1913/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885MGLL 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.